- Policy
- The MFDS encourages production of KF80 masks
- by Lee, Tak-Sun Mar 16, 2020 06:29am
- In order to encourage the KF80 standard health mask to be produced, the MFDS decided to temporarily grant permission to change items that are currently approved under the KF94 standard to KF80. It is judged that the KF80 has less filter requirements than the KF94, which can lead to an increase in mask production. However, there is criti
- Policy
- Korea takes further actions for now-pandemic COVID-19
- by Kim, Jung-Ju Mar 16, 2020 06:28am
- As the outbreak of 2019 novel coronavirus (COVID-19) is spreading worldwide, the Korean government has decided to reinforce prevention of transmission from external source and to take related steps. Besides, the government plans to promptly update ‘Mask App,’ a Smartphone app used for government-issued mask sold at pharmacies. Led by
- Policy
- COVID-19 impacts MOHW pharmaceutical divisions’ personnel
- by Kim, Jung-Ju Mar 16, 2020 06:27am
- Korea’s Ministry of Health and Welfare (MOHW) fighting against COVID-19 outbreak at the forefront, is suffering from manpower vacuum as their directors and senior deputy directors in pharmaceutical affairs have been temporarily transferred. The Pharmaceutical Benefits Division, in charge of pharmaceutical benefit listing, reimbursement stan
- Company
- Handok tops KRW 30 bln PAH treatment market
- by Nho, Byung Chul Mar 16, 2020 06:27am
- Korean pharmaceutical industry is closely paying attention to Handok’s market share constantly growing in pulmonary arterial hypertension (PAH) treatment sector. In 2019, Korean PAH treatment market volume was recorded at 30.7 billion won with 20 percent bump from the previous year. In the market, Handok’s PAH line up&8212;Traclear (6
- Everyone wants to develop COVID-19 treatment
- by choi, sun Mar 15, 2020 06:49pm
- With regard to COVID-19, a number of pharmaceutical biotech companies have announced that they will develop treatments, and interest is being raised as to whether actual products will be available. Some pharmaceutical companies use abstract terminology such as clinical trials and treatment development, but vaccine development must be prof
- Company
- “Lynparza now available for unmet medical needs in TNBC"
- by Eo, Yun-Ho Mar 13, 2020 06:32am
- “Breast cancer has various treatment options.” True, but not always for all types of breast cancer. Since the release of Herceptin (trastuzumab), human epidermal growth factor receptor 2-positive (HER2+) breast cancer treatment paradigm has been shifted and follow-on targeted therapies are continuing to enter the market. The launch of I
- InterView
- CEO Cho Jeong Woo “Cenobamate U.S. release is all ready"
- by Lee, Tak-Sun Mar 13, 2020 06:30am
- A new anti-epileptic drug from SK Biopharmaceuticals, cenobamate (U.S. brand name Xcopri), has set a new milestone in the Korean history of pharmaceutical industry history as it independently won an approval by the U.S. Food and Drug Administration (FDA). To this date, a new drug developed in Korea has been licensed out to foreign pharma
- Company
- Vibramycin & Cefdana are out of stock
- by Jung, Hye-Jin Mar 13, 2020 06:30am
- Some of rescription medicines are sold out. In particular, since Vibramycin-N sold out 500 tablets units in 2018, it is expected that units of 100 tablets will be out of stock, which will cause inconvenience to the prescription site. According to the distribution industry on the 11th, the re-supply of both 100 tablets unit and 500 tablets
- Company
- The Thai government has eased regulations on fillers
- by Kim, Jin-Gu Mar 13, 2020 06:30am
- Export of Hyaluronic acid filler to Thailand becomes easy. This is due to the Thai government's classification of hyaluronic acid fillers as medical devices, not pharmaceuticals, in Thailand starting tomorrow (11th). It is expected that domestic companies' entry into Thailand will accelerate as related certification requirements ease.
- Company
- Bukwang “Levovir as effective as Kaletra on COVID-19”
- by Lee, Seok-Jun Mar 13, 2020 06:30am
- On Mar. 10, Bukwang Pharmaceutical announced its new treatment for hepatitis B Levovir (clevudine) has demonstrated treament effect on par with HIV drug Kaletra, also used to treat COVID-19. According to the Korean company, Levovir has been tested in vitro on virus extracted from Korean COVID-19 patient’s samples. Kaletra’s active
